EU/3/10/816: Orphan designation for the treatment of glioma

7-Beta-hydroxy cholesteryl-3-beta-oleate


On 17 December 2010, orphan designation (EU/3/10/816) was granted by the European Commission to Intsel Chimos SA, France, for 7-beta-hydroxy cholesteryl-3-beta-oleate for the treatment of glioma.

Key facts

Active substance
7-Beta-hydroxy cholesteryl-3-beta-oleate
Intended use
Treatment of glioma
Orphan designation status
EU designation number
Date of designation

162 Bureaux De La Colline
1 Rue Royale
92213 St Cloud Cedex

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

September 2023The sponsorship was transferred from Intsel Chimos SA, France to Glioquest, France.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating